东北制药
(000597)
| 流通市值：67.08亿 | | | 总市值：67.92亿 |
| 流通股本：14.09亿 | | | 总股本：14.27亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 3,332,979,035.72 | 2,006,198,284.03 | 7,074,853,263.92 | 5,478,085,124.55 |
| 营业收入 | 3,332,979,035.72 | 2,006,198,284.03 | 7,074,853,263.92 | 5,478,085,124.55 |
| 二、营业总成本 | 3,191,533,782.39 | 1,926,096,917.42 | 6,671,639,822.19 | 5,196,594,704.99 |
| 营业成本 | 2,252,481,680.29 | 1,435,642,475.18 | 4,437,711,164.91 | 3,559,122,924.57 |
| 税金及附加 | 41,452,704.81 | 19,905,076.21 | 77,093,663.77 | 54,467,926.5 |
| 销售费用 | 443,393,319.14 | 243,321,199.62 | 1,264,523,861.68 | 879,243,019.69 |
| 管理费用 | 362,270,629.99 | 172,614,315.29 | 702,328,686.07 | 590,775,568.39 |
| 研发费用 | 67,866,789.41 | 34,049,538.84 | 172,266,427.48 | 103,963,842.54 |
| 财务费用 | 24,068,658.75 | 20,564,312.28 | 17,716,018.28 | 9,021,423.3 |
| 其中:利息费用 | 19,383,384.07 | 10,648,414.44 | 49,163,074.74 | 35,733,492.89 |
| 其中:利息收入 | 36,002,180.7 | 14,427,262.46 | 90,670,813.43 | 63,805,443.01 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | - | -3,004,970.16 | 350,622.31 | 373,669.04 |
| 加:投资收益 | 247,183.35 | -232,814.15 | 7,809,974.98 | 8,414,313.69 |
| 资产处置收益 | 413,486.39 | 30,613.17 | 255,861.15 | 748,033.03 |
| 资产减值损失(新) | -73,998,122.11 | -64,770,797.08 | -170,904,871.32 | -91,448,958.62 |
| 信用减值损失(新) | -1,184,397.72 | -2,288,139.11 | -4,492,408.75 | -395,965.12 |
| 其他收益 | 35,340,975.45 | 16,054,138.07 | 77,879,262.3 | 72,011,551.68 |
| 四、营业利润 | 102,264,378.69 | 25,889,397.35 | 314,111,882.4 | 271,193,063.26 |
| 加:营业外收入 | 4,159,770.49 | 2,453,619.61 | 52,981,238.56 | 10,976,989.74 |
| 减:营业外支出 | 6,752,078.93 | 213,604.99 | 61,830,077.46 | 42,340,293.45 |
| 五、利润总额 | 99,672,070.25 | 28,129,411.97 | 305,263,043.5 | 239,829,759.55 |
| 减:所得税费用 | 35,867,330.97 | 11,765,620.9 | 87,434,892.49 | 78,785,148.6 |
| 六、净利润 | 63,804,739.28 | 16,363,791.07 | 217,828,151.01 | 161,044,610.95 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 63,804,739.28 | 16,363,791.07 | 217,828,151.01 | 161,044,610.95 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 83,864,614.75 | 26,631,068.38 | 260,070,456.65 | 172,703,081.21 |
| 少数股东损益 | -20,059,875.47 | -10,267,277.31 | -42,242,305.64 | -11,658,470.26 |
| 扣除非经常损益后的净利润 | 57,243,503.69 | 14,774,885.53 | 204,048,702.62 | 132,146,529.56 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.06 | 0.02 | 0.18 | 0.12 |
| (二)稀释每股收益 | 0.06 | 0.02 | 0.18 | 0.12 |
| 八、其他综合收益 | -1,499,967.65 | -740,119.67 | -1,008,512.83 | -506,469.98 |
| 归属于母公司股东的其他综合收益 | -1,505,780.02 | -743,037.86 | -1,012,770.08 | -508,681.3 |
| 九、综合收益总额 | 62,304,771.63 | 15,623,671.4 | 216,819,638.18 | 160,538,140.97 |
| 归属于母公司股东的综合收益总额 | 82,358,834.73 | 25,888,030.52 | 259,057,686.57 | 172,194,399.91 |
| 归属于少数股东的综合收益总额 | -20,054,063.1 | -10,264,359.12 | -42,238,048.39 | -11,656,258.94 |
| 公告日期 | 2026-08-25 | 2026-04-28 | 2026-04-03 | 2025-10-28 |
| 审计意见(境内) | | | 标准无保留意见 | |